All but one of TCTMD’s top 10 stories stemmed from the American College of Cardiology 2024 Scientific Session, and most—but not all—of those were late-breaking clinical trials. Our list this month includes an analysis helping to tease out the disease-modifying benefits (beyond weight loss) of semaglutide, a lower-profile oral device for reducing blood pressure in sleep apnea, and a fresh spotlight on the heart failure risks that follow an at